DR. RAHUL PRASAD

DR. ANTABHA BANDYOPADHYAY, DR. RAHUL PRASAD, Dr..BIBHA KUMARI, Dr.ABHISHEK KUMAR SINHA

Abstract

Aim: to establish hyperreflective walls in foveal cystic spaces as biomarker of Diabetic Macular Edema (DME) refractory to bevacizumab injections.

Method: cross-sectional study was done in 50 patients having center-involved DME (clear media and no other vitreo-retinal disease) visiting tertiary eye center from August 2019 to July 2021 who received multiple monthly bevacizumab injections. Visual outcome and DME remission were correlated with SD-OCT findings at follow up visits till 18 months.

Result: 15 out of 50 cases had hyperreflective walls in foveal cystic spaces on OCT evaluation at follow up visits with no DME remission and poor visual outcome, even after multiple bevacizumab injections (p < 0.05). Mean follow up was 20 ± 3 months. Outcome also depended upon baseline visual acuity, blood sugar control and severity of DME before Anti-VEGF therapy. Conclusion: hyperreflective walls in foveal cystic spaces can predict DME refractory to anti-VEGF drugs.

Full Text